The IgA Nephropathy disease treatment market is projected to grow at a CAGR of 17.27% during the forecast period to reach US$391.608 million by 2027, from US$128.428 million in 2020.
IgA Nephropathy (IgAN), commonly known as Berger's disease, is rare autoimmune kidney disease. It obstructs blood filtration in the small blood channels of the kidneys. IgA Nephropathy is caused by an abnormal protein that kills the filtering unit (glomerulus) inside the kidneys. It is thought that 20–40% of people with IgA Nephropathy may develop end-stage kidney failure, requiring dialysis or kidney transplantation. It can manifest itself in many ways, from asymptomatic microscopic hematuria to rapidly progressive GN. The typical mode of presentation varies depending on the age group and biopsy practice patterns. IgA Nephropathy disease treatment consists of medications that assist manage symptoms such as high blood pressure, protein in the urine, and edema, as well as slow the progression of the disease. Though the actual etiology of the illness is unknown, a variety of immunosuppressants, or immune-suppressing drugs, such as steroids, are being considered.
One of the key reasons driving the IgA Nephropathy disease treatment market during the forecast period is the rising number of cases of IgA Nephropathy around the world. The increasing cases have influenced the demand for novel medications for IgA Nephropathy treatment. The growing interest in a better knowledge of illness pathophysiology and the lack of particular treatment options will propel the market forward throughout the forecast period. Furthermore, rising health awareness will fuel market expansion due to early disease detection.
IgA Nephropathy disease affects a small, heterogeneous, and widely dispersed patient population, making clinical trial enrolment, design, and replication more difficult. This process wastes crucial time, delays access to new medicines, and causes significant losses. Measuring clinical trial outcomes in patients is difficult due to the wide range of clinical presentations and histories. Variables such as age, disease progression, and severity influence reported outcomes, whether clinician-reported, observer-reported, or patient-reported. Given the relative rarity of IgA Nephropathy, robust trials have generally been hampered by limited enrolment, and there has been a scarcity of worldwide recruiting clinical research trials.
By tests, the IgA Nephropathy disease treatment market is segmented into blood tests, urine tests, glomerular filtration rate (GFR), kidney biopsy, and others.
By treatment type, the IgA Nephropathy disease treatment market is segmented into corticosteroids, therapy, immunosuppressive drugs, ACE inhibitors and ARBs, and diet change. Two of the most frequent IgA Nephropathy treatments are angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin-receptor blockers (ARBs).
By geography, the IgA Nephropathy disease treatment market is segmented into five regions North America, Europe, South America, the Middle East and Africa, and the Asia Pacific regions. Because of the increased demand for IgA nephropathy by academics and scientists, North America is projected to dominate the market. The United States is expected to hold a major market share as the disease is one of the main reasons for acute nephritis among young people in the region. Due to advancement and increased demand for more IgA nephropathy products and services, Europe is predicted to grow substantially. The Asia-Pacific region is predicted to grow at the quickest CAGR during the forecast period, as demand for modern IgA nephropathy products increases in countries like China and the Asia Pacific region.
Due to the COVID-19 pandemic lockdown, measures were placed, preventing patient movement and likely identification and overburdening healthcare systems. The COVID 19 epidemic would lead to an extremely slow turnaround time for patients undergoing selected procedures. Even if fully vaccinated, those with renal illness at any stage and kidney transplant recipients may not have as much protection against the virus. COVID-19 sickness appears to be more severe in older adults and people with kidney diseases such as IgA Nephropathy or other severe chronic medical conditions.
|Market size value in 2020||US$128.428 million|
|Market size value in 2027||US$391.608 million|
|Growth Rate||CAGR of 17.27% from 2019 to 2026|
|Forecast Unit (Value)||USD Million|
|Segments covered||Test, Treatment Type, And Geography|
|Regions covered||North America, South America, Europe, Middle East and Africa, Asia Pacific|
|Companies covered||Travere Therapeutics Inc., Calliditas Therapeutics AB, Omeros, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., Merck KGaA, Darmstadt, Germany, Reata Pharmaceuticals, Inc., Ionis Pharmaceuticals, Apellis Pharmaceuticals|
|Customization scope||Free report customization with purchase|
Key Market Segments
Frequently Asked Questions (FAQs)
Q1. What will be the IgA nephropathy disease treatment market size by 2027?
A1. The global IgA nephropathy disease treatment market is projected to reach a market size of US$391.608 millionn by 2027.
Q2. What is the size of the global IgA nephropathy disease treatment market?
A2. IgA Nephropathy Disease Treatment Market was valued at US$128.428 million in 2020.
Q3. What are the growth prospects for the IgA nephropathy disease treatment market?
A3. The IgA nephropathy disease treatment market is projected to grow at a CAGR of 17.27% over the forecast period.
Q4. Which region holds the largest market share in the IgA nephropathy disease treatment market?
A4. North America is projected to dominate the IgA nephropathy disease treatment market due to the increased demand for IgA nephropathy by academics and scientists in the region.
Q5. What factors are anticipated to drive the IgA nephropathy disease treatment market growth?
A5. One of the key reasons driving the IgA Nephropathy disease treatment market is the rising number of cases of IgA Nephropathy around the world.
1.1. Market Overview
1.2. Covid-19 Scenario
1.3. Market Definition
1.4. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Powers of Buyers
4.3.3. Threat of Substitutes
4.3.4. The threat of New Entrants
4.3.5. Competitive Rivalry in Industry
4.4. Industry Value Chain Analysis
5. IGA NEPHROPATHY DISEASE TREATMENT MARKET, BY TEST
5.2. Blood test
5.3. Urine test
5.4. Kidney biopsy
5.5. Iothalamate clearance test
6. IGA NEPHROPATHY DISEASE TREATMENT MARKET, BY TREATMENT TYPE
6.3. Immunosuppressive drugs
6.4. ACE inhibitors and ARBs
6.5. Diet Change
7. IGA NEPHROPATHY DISEASE TREATMENT MARKET, BY GEOGRAPHY
7.2. North America
7.2.1. United States
7.3. South America
7.4.1. United Kingdom
7.5. Middle East and Africa
7.5.1. Saudi Arabia
7.6. Asia Pacific
7.6.4. South Korea
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrative
8.3. Mergers, Acquisition, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. COMPANY PROFILES
9.1. Travere Therapeutics Inc.
9.2. Calliditas Therapeutics AB
9.4. Novartis Pharmaceuticals
9.5. Chinook Therapeutics, Inc.
9.6. Vera Therapeutics, Inc.
9.7. Merck KGaA, Darmstadt, Germany
9.8. Reata Pharmaceuticals, Inc.
9.9. Ionis Pharmaceuticals
9.10. Apellis Pharmaceuticals
Travere Therapeutics Inc.
Calliditas Therapeutics AB
Chinook Therapeutics, Inc.
Vera Therapeutics, Inc.
Merck KGaA, Darmstadt, Germany
Reata Pharmaceuticals, Inc.
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.